ClinicalTrials.gg
CompletedNCT02527434Updated Nov 15, 2023Results posted

Study of Tremelimumab in Patients With Advanced Solid Tumors

A Phase 2 interventional study of Tremelimumab monotherapy and MEDI4736 monotherapy in Urothelial Bladder Cancer, Triple-negative Breast Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by AstraZeneca. Completed at 14 sites in 5 countries. Open to participants aged 18 Years to 150 Years. Per ClinicalTrials.gov, last updated 2023-11-15.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
64
Allocation
Not applicable
Ages
18 Years to 150 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies in Triple Negative Breast Neoplasms by AstraZeneca — 1 open to participants now, 6 under way, 1 of them phase 3. Triple Negative Breast Neoplasms · AstraZeneca.

Enrollment
11th of 15
64 · median 99
Started
2015
with 1 other
Phase 2
3 of 15
none open now
Registered
5th of 15
by date

Among the 15 studies in Triple Negative Breast Neoplasms by AstraZeneca, this one is the 11th largest by enrollment, is one of 2 that started in 2015, is one of 3 in phase 2, and was the 5th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

1 of the 15 studies in Triple Negative Breast Neoplasms by AstraZeneca is open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 331 Triple Negative Breast Neoplasms studies recruiting now, 231 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 150 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Triple Negative Breast Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients with Advanced Solid Tumors

Read the detailed description

This is an open-label, multi-center study to determine the efficacy and safety of tremelimumab in the treatment of different cohorts of patients with selected advanced solid tumors. If eligible and at the discretion of the Investigator, after confirmed disease progression on tremelimumab monotherapy or during follow-up, patients will have the option of being sequenced to MEDI4736 (MedImmune 4736) monotherapy or MEDI4736 + tremelimumab combination therapy, for up to 12 months or until disease progression, whichever comes sooner.

03

Conditions studied

  • Urothelial Bladder Cancer
  • Triple-negative Breast Cancer
  • Pancreatic Ductal Adenocarcinoma

Keywords

  • Urothelial bladder cancer, Triple-negative breast cancer, Pancreatic ductal adenocarcinoma, Advanced Solid Tumors, Tremelimumab, MEDI4736, ORR
04

Who can participate

Ages eligible
18 Years to 150 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically documented solid tumor , including but not limited to 1 of the following: UBC, PDAC, TNBC; Are intolerant, are ineligible for, or have refused treatment with standard therapy; 2. At least 1 lesion, not previously irradiated, that can be accurately measured at baseline as ≥10 mm in the longest diameter (except lymph nodes, which must have short axis ≥15 mm) with computed tomography (CT) (preferred) or magnetic resonance imaging (MRI) scans and that is suitable for accurate repeated measurements.

Exclusion criteria

Exclusion criteria:

  1. Any concurrent chemotherapy, biologic, or hormonal therapy for cancer Treatment; 2. History of ; 3. Active or prior documented or inflammatory disorders; 4. or spinal cord compression unless asymptomatic or treated and stable off and anti-convulsants for at least 14 days prior to study treatment start; 5. corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms; 6. Known allergy or to IP or any IP
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    treme mono to be sequenced to MEDI4736 mono or combination

    tremelimumab monotherapy, with the option for eligible patients to be sequenced to MEDI4736 monotherapy or MEDI4736 + tremelimumab combination therapy after progressive disease (PD)

    Biological: Tremelimumab monotherapy · Biological: MEDI4736 monotherapy · Biological: MEDI4736 + tremelimumab combination therapy

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Patients With Confirmed Overall Response During Tremelimumab Monotherapy Phase

    Objective response rate (ORR) during the initial tremelimumab monotherapy phase was assessed by the site Investigator using Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1) and was defined as the percentage of patients with a confirmed overall response of complete response (CR) or partial response (PR) and was based on all treated patients who had measurable disease at baseline (Day 1). 95% confidence intervals (CIs) were calculated using the Clopper Pearson method.

    Time frame: From baseline to 12 months in the tremelimumab monotherapy phase

Secondary outcomes

  1. Median Duration of Response (DoR) During Tremelimumab Monotherapy Phase

    DoR during the initial tremelimumab monotherapy phase was assessed by the site Investigator using RECIST 1.1 and was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression. The time of the initial response was defined as the latest of the dates contributing toward the first visit response of CR or PR. If a patient did not progress following a response, then their DoR was censored at the progression-free survival (PFS) censoring time. DoR was not defined for those patients who did not have documented response. Median DoR was calculated using the Kaplan-Meier technique.

    Time frame: From baseline to 12 months in the tremelimumab monotherapy phase

  2. Disease Control Rate (DCR) During Tremelimumab Monotherapy Phase

    DCR during the initial tremelimumab monotherapy phase was defined as the percentage of patients who had a best objective response (BoR) of CR or PR in the first 3 months (PDAC patients) or 4 months (UBC and TNBC patients) and 12 months (all patients), or who had demonstrated stable disease (SD) for a minimum interval of 3, 4 or 12 months following the start of study treatment. DCR was determined programmatically based on RECIST 1.1 using site Investigator data and all data up until the first progression event. 95% CIs were calculated using the Clopper Pearson method.

    Time frame: From baseline to 12 months in the tremelimumab monotherapy phase

  3. Median PFS During Tremelimumab Monotherapy Phase

    PFS during the initial tremelimumab monotherapy phase was assessed by the site Investigator using RECIST 1.1 and was defined as the time from the date of enrollment until the date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the patient withdrew from therapy or received another anticancer therapy prior to progression. Progression events that did not occur within 3 months (PDAC patients) or 4 months (UBC/TNBC patients) of the last evaluable assessment (or first dose) were censored. Median PFS was calculated using the Kaplan-Meier technique.

    Time frame: From baseline to 12 months in the tremelimumab monotherapy phase

  4. Best Objective Response (BoR) During Tremelimumab Monotherapy Phase

    BoR during the initial tremelimumab monotherapy phase was calculated based on the overall visit responses from each RECIST 1.1 assessment and was defined as the best response a patient had during their time in the study (from CR, PR, SD, PD or not evaluable \[NE\]) obtained among all tumor assessment visits from baseline until end of treatment or determination of PD. The BoR was summarized by percentage of patients for each category (CR, PR, SD, PD, and NE).

    Time frame: From baseline to 12 months in the tremelimumab monotherapy phase

  5. Median Overall Survival (OS) During Tremelimumab Monotherapy Phase

    OS was defined as the time from the date of first dose until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. OS is presented from start of tremelimumab monotherapy phase and includes the retreatment phase if the patient entered the corresponding treatment phase. Median OS was calculated using the Kaplan-Meier technique.

    Time frame: From baseline to final data cut-off date

  6. Percentage of Patients With Confirmed Overall Response During Retreatment Phase

    ORR was assessed by the site Investigator using RECIST 1.1 and was defined as the percentage of patients with a confirmed overall response of CR or PR and was based on all treated patients who had measurable disease at baseline (Day 1) and who sequenced to durvalumab monotherapy (MEDI treatment phase) or durvalumab + tremelimumab combination therapy (COMBO treatment phase). 95% CIs were calculated using the Clopper Pearson method.

    Time frame: From baseline to 12 months in retreatment phase

  7. Median DoR During Retreatment Phase

    DoR during the retreatment phase was assessed by the site Investigator using RECIST 1.1 and was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression. The time of the initial response was defined as the latest of the dates contributing toward the first visit response of CR or PR. If a patient did not progress following a response, then their DoR was censored at the PFS censoring time. DoR was not defined for those patients who did not have documented response. Median DoR was calculated using the Kaplan-Meier technique.

    Time frame: From baseline to 12 months in retreatment phase

  8. DCR During Retreatment Phase

    DCR during the retreatment phase was defined as the percentage of patients who had a BoR of CR or PR in the first 3 months (PDAC patients) or 4 months (UBC and TNBC patients) or who had demonstrated SD for a minimum interval of 3 or 4 months following the start of study treatment. DCR was determined programmatically based on RECIST 1.1 using site Investigator data and all data up until the first progression event. 95% CIs were calculated using the Clopper Pearson method.

    Time frame: From baseline to 4 months in retreatment phase

  9. Median PFS During Retreatment Phase

    PFS during the retreatment phase was assessed by the site Investigator using RECIST 1.1 and defined as the time from the date of enrollment until the date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the patient withdrew from therapy or received another anticancer therapy prior to progression. Progression events that did not occur within 3 months (PDAC patients) or 4 months (UBC/TNBC patients) of the last evaluable assessment (or first dose) were censored. Median PFS was calculated using the Kaplan-Meier technique.

    Time frame: From baseline to 12 months in retreatment phase

  10. BoR During Retreatment Phase

    BoR during the retreatment phase was calculated based on the overall visit responses from each RECIST 1.1 assessment and was defined as the best response a patient had during their time in the study (from CR, PR, SD, PD or NE) obtained among all tumor assessment visits from baseline until end of treatment or determination of PD. The BoR was summarized by percentage of patients for each category (CR, PR, SD, PD, and NE).

    Time frame: From baseline to 12 months in retreatment phase

  11. Median OS During Retreatment Phase

    OS during the retreatment phase was defined as the time from the date of first dose until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique.

    Time frame: From baseline in retreatment phase to final data cut-off date

07

Results

Posted Mar 5, 2019

Participant flow

A total of 64 patients with select advanced solid tumors were treated in this phase II, open-label, multi-center study from November 2015. Primary data cut off date: 17 February 2018. Final data cut off date: 31 December 2018.

Participant flow — Overall Study
MilestoneUBC CohortTNBC CohortPDAC Cohort
Started321220
Started retreatment phase (combo)754
Started retreatment phase (medi)401
Completed410
Not completed281120
Withdrew: Lost to follow-up220
Withdrew: Death19617
Withdrew: Withdrawal by subject533
Withdrew: Reason not specified100
Withdrew: Site closure100

Outcome measures

PrimaryPercentage of Patients With Confirmed Overall Response During Tremelimumab Monotherapy Phase

Objective response rate (ORR) during the initial tremelimumab monotherapy phase was assessed by the site Investigator using Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1) and was defined as the percentage of patients with a confirmed overall response of complete response (CR) or partial response (PR) and was based on all treated patients who had measurable disease at baseline (Day 1). 95% confidence intervals (CIs) were calculated using the Clopper Pearson method.

Time frame:
From baseline to 12 months in the tremelimumab monotherapy phase
Reported as:
Number · Percentage of Patients
Percentage of Patients With Confirmed Overall Response During Tremelimumab Monotherapy Phase
Percentage of PatientsUBC - Tremelimumab MonotherapyTNBC - Tremelimumab MonotherapyPDAC - Tremelimumab Monotherapy
Percentage of Patients With Confirmed Overall Response During Tremelimumab Monotherapy Phase18.8 (7.2 to 36.4)8.3 (0.2 to 38.5)0.0 (0.0 to 16.8)
SecondaryMedian Duration of Response (DoR) During Tremelimumab Monotherapy Phase

DoR during the initial tremelimumab monotherapy phase was assessed by the site Investigator using RECIST 1.1 and was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression. The time of the initial response was defined as the latest of the dates contributing toward the first visit response of CR or PR. If a patient did not progress following a response, then their DoR was censored at the progression-free survival (PFS) censoring time. DoR was not defined for those patients who did not have documented response. Median DoR was calculated using the Kaplan-Meier technique.

Time frame:
From baseline to 12 months in the tremelimumab monotherapy phase
Reported as:
Median · Months
Median Duration of Response (DoR) During Tremelimumab Monotherapy Phase
MonthsUBC - Tremelimumab MonotherapyTNBC - Tremelimumab MonotherapyPDAC - Tremelimumab Monotherapy
Median Duration of Response (DoR) During Tremelimumab Monotherapy PhaseNA (NA to NA)12.9 (12.9 to 12.9)NA (NA to NA)
SecondaryDisease Control Rate (DCR) During Tremelimumab Monotherapy Phase

DCR during the initial tremelimumab monotherapy phase was defined as the percentage of patients who had a best objective response (BoR) of CR or PR in the first 3 months (PDAC patients) or 4 months (UBC and TNBC patients) and 12 months (all patients), or who had demonstrated stable disease (SD) for a minimum interval of 3, 4 or 12 months following the start of study treatment. DCR was determined programmatically based on RECIST 1.1 using site Investigator data and all data up until the first progression event. 95% CIs were calculated using the Clopper Pearson method.

Time frame:
From baseline to 12 months in the tremelimumab monotherapy phase
Reported as:
Number · Percentage of patients
Disease Control Rate (DCR) During Tremelimumab Monotherapy Phase
Percentage of patientsUBC - Tremelimumab MonotherapyTNBC - Tremelimumab MonotherapyPDAC - Tremelimumab Monotherapy
DCR at 3 or 4 months25.0 (11.46 to 43.40)8.3 (0.21 to 38.48)0.0 (0.00 to 16.84)
DCR at 12 months21.9 (9.28 to 39.97)8.3 (0.21 to 38.48)0.0 (0.00 to 16.84)
SecondaryMedian PFS During Tremelimumab Monotherapy Phase

PFS during the initial tremelimumab monotherapy phase was assessed by the site Investigator using RECIST 1.1 and was defined as the time from the date of enrollment until the date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the patient withdrew from therapy or received another anticancer therapy prior to progression. Progression events that did not occur within 3 months (PDAC patients) or 4 months (UBC/TNBC patients) of the last evaluable assessment (or first dose) were censored. Median PFS was calculated using the Kaplan-Meier technique.

Time frame:
From baseline to 12 months in the tremelimumab monotherapy phase
Reported as:
Median · Months
Median PFS During Tremelimumab Monotherapy Phase
MonthsUBC - Tremelimumab MonotherapyTNBC - Tremelimumab MonotherapyPDAC - Tremelimumab Monotherapy
Median PFS During Tremelimumab Monotherapy Phase2.63 (1.77 to NA)3.58 (1.40 to 4.04)1.77 (1.38 to 2.92)
SecondaryBest Objective Response (BoR) During Tremelimumab Monotherapy Phase

BoR during the initial tremelimumab monotherapy phase was calculated based on the overall visit responses from each RECIST 1.1 assessment and was defined as the best response a patient had during their time in the study (from CR, PR, SD, PD or not evaluable \[NE\]) obtained among all tumor assessment visits from baseline until end of treatment or determination of PD. The BoR was summarized by percentage of patients for each category (CR, PR, SD, PD, and NE).

Time frame:
From baseline to 12 months in the tremelimumab monotherapy phase
Reported as:
Number · Percentage of Patients
Best Objective Response (BoR) During Tremelimumab Monotherapy Phase
Percentage of PatientsUBC - Tremelimumab MonotherapyTNBC - Tremelimumab MonotherapyPDAC - Tremelimumab Monotherapy
CR6.30.00.0
PR12.58.30.0
SD9.40.00.0
PD68.891.790.0
NE3.10.010.0
SecondaryMedian Overall Survival (OS) During Tremelimumab Monotherapy Phase

OS was defined as the time from the date of first dose until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. OS is presented from start of tremelimumab monotherapy phase and includes the retreatment phase if the patient entered the corresponding treatment phase. Median OS was calculated using the Kaplan-Meier technique.

Time frame:
From baseline to final data cut-off date
Reported as:
Median · Months
Median Overall Survival (OS) During Tremelimumab Monotherapy Phase
MonthsUBC - Tremelimumab MonotherapyTNBC - Tremelimumab MonotherapyPDAC - Tremelimumab Monotherapy
Median Overall Survival (OS) During Tremelimumab Monotherapy Phase10.32 (5.91 to 24.61)12.88 (2.53 to NA)3.98 (2.83 to 5.13)
SecondaryPercentage of Patients With Confirmed Overall Response During Retreatment Phase

ORR was assessed by the site Investigator using RECIST 1.1 and was defined as the percentage of patients with a confirmed overall response of CR or PR and was based on all treated patients who had measurable disease at baseline (Day 1) and who sequenced to durvalumab monotherapy (MEDI treatment phase) or durvalumab + tremelimumab combination therapy (COMBO treatment phase). 95% CIs were calculated using the Clopper Pearson method.

Time frame:
From baseline to 12 months in retreatment phase
Reported as:
Number · Percentage of Patients
Percentage of Patients With Confirmed Overall Response During Retreatment Phase
Percentage of PatientsUBC - COMBOTNBC - COMBOPDAC - COMBOUBC- MEDIPDAC - MEDI
Percentage of Patients With Confirmed Overall Response During Retreatment Phase0.0 (0.0 to 41.0)0.0 (0.0 to 52.2)0.0 (0.0 to 60.2)25.0 (0.6 to 80.6)0.0 (0.0 to 97.5)
SecondaryMedian DoR During Retreatment Phase

DoR during the retreatment phase was assessed by the site Investigator using RECIST 1.1 and was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression. The time of the initial response was defined as the latest of the dates contributing toward the first visit response of CR or PR. If a patient did not progress following a response, then their DoR was censored at the PFS censoring time. DoR was not defined for those patients who did not have documented response. Median DoR was calculated using the Kaplan-Meier technique.

Time frame:
From baseline to 12 months in retreatment phase
Reported as:
Median · Months
Median DoR During Retreatment Phase
MonthsUBC - COMBOTNBC - COMBOPDAC - COMBOUBC- MEDIPDAC - MEDI
Median DoR During Retreatment PhaseNA (NA to NA)NA (NA to NA)NA (NA to NA)7.3 (7.3 to 7.3)NA (NA to NA)
SecondaryDCR During Retreatment Phase

DCR during the retreatment phase was defined as the percentage of patients who had a BoR of CR or PR in the first 3 months (PDAC patients) or 4 months (UBC and TNBC patients) or who had demonstrated SD for a minimum interval of 3 or 4 months following the start of study treatment. DCR was determined programmatically based on RECIST 1.1 using site Investigator data and all data up until the first progression event. 95% CIs were calculated using the Clopper Pearson method.

Time frame:
From baseline to 4 months in retreatment phase
Reported as:
Number · Percentage of Patients
DCR During Retreatment Phase
Percentage of PatientsUBC - COMBOTNBC - COMBOPDAC - COMBOUBC- MEDIPDAC - MEDI
DCR During Retreatment Phase28.6 (3.67 to 70.96)20.0 (0.51 to 71.64)25.0 (0.63 to 80.59)25.0 (0.63 to 80.59)0.0 (0.00 to 97.50)
SecondaryMedian PFS During Retreatment Phase

PFS during the retreatment phase was assessed by the site Investigator using RECIST 1.1 and defined as the time from the date of enrollment until the date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the patient withdrew from therapy or received another anticancer therapy prior to progression. Progression events that did not occur within 3 months (PDAC patients) or 4 months (UBC/TNBC patients) of the last evaluable assessment (or first dose) were censored. Median PFS was calculated using the Kaplan-Meier technique.

Time frame:
From baseline to 12 months in retreatment phase
Reported as:
Median · Months
Median PFS During Retreatment Phase
MonthsUBC - COMBOTNBC - COMBOPDAC - COMBOUBC- MEDIPDAC - MEDI
Median PFS During Retreatment Phase2.83 (1.81 to 3.65)0.99 (0.92 to NA)2.86 (1.87 to 3.52)2.86 (1.81 to 6.62)1.84 (1.84 to 1.84)
SecondaryBoR During Retreatment Phase

BoR during the retreatment phase was calculated based on the overall visit responses from each RECIST 1.1 assessment and was defined as the best response a patient had during their time in the study (from CR, PR, SD, PD or NE) obtained among all tumor assessment visits from baseline until end of treatment or determination of PD. The BoR was summarized by percentage of patients for each category (CR, PR, SD, PD, and NE).

Time frame:
From baseline to 12 months in retreatment phase
Reported as:
Number · Percentage of Patients
BoR During Retreatment Phase
Percentage of PatientsUBC - COMBOTNBC - COMBOPDAC - COMBOUBC- MEDIPDAC - MEDI
CR0.00.00.00.00.0
PR0.00.00.025.00.0
SD14.320.00.00.00.0
PD71.480.0100.075.0100.0
NE14.30.00.00.00.0
SecondaryMedian OS During Retreatment Phase

OS during the retreatment phase was defined as the time from the date of first dose until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique.

Time frame:
From baseline in retreatment phase to final data cut-off date
Reported as:
Median · Months
Median OS During Retreatment Phase
MonthsUBC - COMBOTNBC - COMBOPDAC - COMBOUBC- MEDIPDAC - MEDI
Median OS During Retreatment Phase11.86 (5.91 to NA)33.05 (9.69 to 33.05)7.18 (3.98 to 18.76)16.53 (7.56 to 32.39)4.14 (NA to NA)

Adverse events

Collected over Adverse events were collected from Day 1 (i.e. first dose) up until 90 days following the end of treatment in the tremelimumab monotherapy phase and the retreatment phase (up to a total of 15 months per treatment phase).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
UBC- Tremelimumab Monotherapy13/32 (40.6%)18/32 (56.3%)30/32 (93.8%)
TNBC - Tremelimumab Monotherapy4/12 (33.3%)4/12 (33.3%)10/12 (83.3%)
PDAC- Tremelimumab Monotherapy12/20 (60%)11/20 (55%)19/20 (95%)
UBC - COMBO4/7 (57.1%)3/7 (42.9%)7/7 (100%)
TNBC - COMBO2/5 (40%)2/5 (40%)5/5 (100%)
PDAC - COMBO4/4 (100%)3/4 (75%)4/4 (100%)
UBC- MEDI4/4 (100%)1/4 (25%)4/4 (100%)
PDAC - MEDI1/1 (100%)0/1 (0%)1/1 (100%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
EventUBC- Tremelimumab MonotherapyTNBC - Tremelimumab MonotherapyPDAC- Tremelimumab MonotherapyUBC - COMBOTNBC - COMBOPDAC - COMBOUBC- MEDIPDAC - MEDI
AnaemiaBlood and lymphatic system disorders0/320/120/200/70/50/41/40/1
DiarrhoeaGastrointestinal disorders4/320/123/200/70/51/40/40/1
Large intestinal obstructionGastrointestinal disorders0/320/120/200/70/51/40/40/1
Jaundice cholestaticHepatobiliary disorders0/320/120/200/70/51/40/40/1
EncephalopathyNervous system disorders0/320/120/200/70/51/40/40/1
PneumonitisRespiratory, thoracic and mediastinal disorders0/320/121/200/70/51/40/40/1
Diarrhoea haemorrhagicGastrointestinal disorders0/320/120/200/71/50/40/40/1
AstheniaGeneral disorders0/320/120/201/71/50/40/40/1
HyponatraemiaMetabolism and nutrition disorders0/322/120/200/70/50/40/40/1
Confusional statePsychiatric disorders1/320/120/201/70/50/40/40/1
Most frequent other events
Showing 10 of 107
Most frequent other events
EventUBC- Tremelimumab MonotherapyTNBC - Tremelimumab MonotherapyPDAC- Tremelimumab MonotherapyUBC - COMBOTNBC - COMBOPDAC - COMBOUBC- MEDIPDAC - MEDI
VomitingGastrointestinal disorders4/322/122/200/71/51/40/41/1
AstheniaGeneral disorders0/320/121/201/70/52/40/41/1
DizzinessNervous system disorders1/321/120/200/70/50/40/41/1
Decreased appetiteMetabolism and nutrition disorders7/322/125/201/74/51/40/40/1
Productive coughRespiratory, thoracic and mediastinal disorders0/322/120/200/73/50/40/40/1
HyponatraemiaMetabolism and nutrition disorders1/322/123/200/72/52/40/40/1
FatigueGeneral disorders15/321/126/202/70/50/41/40/1
ConstipationGastrointestinal disorders9/325/123/200/71/51/40/40/1
PruritusSkin and subcutaneous tissue disorders8/325/127/201/72/51/40/40/1
Weight decreasedInvestigations4/320/122/200/72/50/40/40/1

Baseline characteristics

Analysis was performed on the FAS (all treated patients who received at least 1 dose of tremelimumab monotherapy).

Age, Categorical
Age, Categorical(Participants)UBC CohortTNBC CohortPDAC CohortTotal
<=18 years0000
Between 18 and 65 years1381435
>=65 years194629
Sex: Female, Male
Sex: Female, Male(Participants)UBC CohortTNBC CohortPDAC CohortTotal
Female612927
Male2601137
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)UBC CohortTNBC CohortPDAC CohortTotal
Hispanic or Latino1001
Not Hispanic or Latino31122063
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)UBC CohortTNBC CohortPDAC CohortTotal
American Indian or Alaska Native0000
Asian10111132
Native Hawaiian or Other Pacific Islander0000
Black or African American0011
White211830
More than one race0000
Unknown or Not Reported1001
08

Study locations

14 sites
  • Research Site
    San Francisco, California 94158, United States
  • Research Site
    Memphis, Tennessee 38120, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Brussels, 1090, Belgium
  • Research Site
    Charleroi, 6000, Belgium
  • Research Site
    Wilrijk, 2610, Belgium
  • Research Site
    Daejeon, 35015, Korea, Republic of
  • Research Site
    Seoul, 03080, Korea, Republic of
  • Research Site
    Seoul, 03722, Korea, Republic of
  • Research Site
    Seoul, 135-710, Korea, Republic of
  • Research Site
    Groningen, 9713 GZ, Netherlands
  • Research Site
    Utrecht, 3584 CX, Netherlands
  • Research Site
    Gdańsk, 80-214, Poland
  • Research Site
    Łódź, 93-513, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Feb 2018, 27 months.

Results were first posted in Mar 2019, 1 year after primary completion.

Of 255 phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 94. This study's 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2015
First posted
Aug 19, 2015
StartActual
Nov 2, 2015
Primary completionActual
Feb 17, 2018
CompletionActual
Mar 28, 2023
Results first posted
Mar 5, 2019
Last update
Nov 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02527434
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 19, 2015
Start date
Nov 2, 2015
Primary completion
Feb 17, 2018
Completion
Mar 28, 2023
Results posted
Mar 5, 2019
Last update
Nov 15, 2023

Study contacts

Sharma Padmanee, MD, PhD
principal investigator · Anderson Cancer Center, the University of Texas

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tremelimumab

Start the discussion